Jilin Aodong subsidiary secures drug registration for Terbutaline Sulfate Nebuliser Solution

Jilin Aodong Pharmaceutical Group announced today that its controlled subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd. (Yanji Pharmaceutical), has been granted a drug registration certificate for "Terbutaline Sulfate Nebuliser Solution" by the National Medical Products Administration. The certificate was issued following the approval of the chemical drug, classified as Category 4.

The drug, with a specification of 2ml:5mg, is an inhaled preparation primarily composed of terbutaline sulfate. Its approved use is for relieving bronchospasm associated with bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases. The certificate is valid until September 1, 2030.

This new registration is expected to enhance Jilin Aodong Pharmaceutical Group's product structure and diversity, bolstering its core competitiveness and providing a foundation for steady growth. Yanji Pharmaceutical is listed as the marketing authorization holder and manufacturer.

The company stated that while this approval creates favorable conditions for future development, the sales performance of the product will be subject to market changes, introducing uncertainty. Jilin Aodong advises investors to exercise caution, noting that the new registration is not expected to significantly impact the company's short-term financial performance.